. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: J Heart Lung Transplant. 2015 Oct 19;35(3):342–351. doi: 10.1016/j.healun.2015.10.019

Table 4.

Plasma aldosterone levels according to mineralocorticoid receptor antagonist therapy status.

	HFrEF Patients
Aldosterone levels (ng/dl)	−MR Antagonist Therapy (N=25)	+MR Antagonist Therapy (N=17)	P Value
Resting PA	558.0 [391.5–558.0]	700.5 [451.9–9–902.5]	0.44
Resting Radial	568.5 [411.0–904.8]	732.0 [606.0–1217]	0.51
Peak PA	594.0 [457.5–1146]	712.5 [513.0–1036]	0.65
Peak Radial	699.0 [471.6–904.8]	735.0 [465.0–1180]	0.77

Plasma radial and pulmonary arterial (PA) aldosterone levels acquired at rest or during peak exercise (peak) patients with heart failure preserved ejection fraction (HFrEF) referred for cardiopulmonary exercise testing were analyzed according to mineralocorticoid receptor (MR) antagonism use.